Skip to content
Home/Companies/Biotech/Eliem Therapeutics

Eliem Therapeutics

Biotech·United States·Exited 2021·Held under 1yr
Entry
2021
Hold
<1yr
Exit
2021

Who owns Eliem Therapeutics?

Eliem Therapeutics was owned by LifeArc through LifeArc Ventures (1992 vintage) from 2021 to 2021, exited via IPO.

Hand-verified · updated 2026-08-03

LifeArc
Investor
LifeArc
LifeArc Ventures · 1992 · Life Sciences VC

Key facts

HQUnited States
SectorBiotech
StatusAcquired
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2021

More from LifeArc Ventures

Other portfolio companies in the same fund.

Exciva
Active
BiotechGermany· 2026
GlycoEra
Active
BiotechSwitzerland· 2025
Hillstar Bio
Active
BiotechUnited States· 2025
Tribune Therapeutics
Active
BiotechSweden· 2025
Fluid Biomed
Fluid Biomed
Active
MedTechCanada· 2024
Affect Therapeutics
Affect Therapeutics
Active
HealthTechUnited States· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Eliem Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Eliem Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue